The French pharmaceutical giant Sanofi has announced a restructuring plan for its R&D activities and support functions that will result in 1,680 jobs cuts in the next three years in Europe, mainly in France where 1,000 job cuts are expected. The job reductions will affect support functions, sales and research-related platforms. No plant closures are to be expected. This plan, which will be spread over three years, is not linked to the consequences of Covid-19. It corresponds to a new strategy announced in December 2019. The aim is to make €2 billion in savings and to concentrate on a few promising niches. On the agenda: the end of research in diabetes, one of its traditional core businesses, as well as in the cardiovascular field. A worldwide restructuring was recorded in 2011 (1,400 to 3,000 job cuts in R&D, announced in 2011).